Shares of Translate Bio Inc (NASDAQ:TBIO) have been assigned a consensus rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $22.75.
A number of analysts recently commented on TBIO shares. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Translate Bio in a report on Tuesday, April 9th. ValuEngine downgraded shares of Translate Bio from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, Zacks Investment Research downgraded shares of Translate Bio from a “hold” rating to a “sell” rating in a report on Saturday.
TBIO stock opened at $11.34 on Friday. Translate Bio has a 52 week low of $4.81 and a 52 week high of $16.60. The company has a debt-to-equity ratio of 0.83, a current ratio of 10.47 and a quick ratio of 10.47.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in shares of Translate Bio by 139.0% in the 4th quarter. Geode Capital Management LLC now owns 117,432 shares of the company’s stock worth $880,000 after purchasing an additional 68,300 shares during the last quarter. Norges Bank acquired a new position in shares of Translate Bio in the 4th quarter worth approximately $263,000. FMR LLC grew its stake in shares of Translate Bio by 6.8% in the 4th quarter. FMR LLC now owns 6,771,313 shares of the company’s stock worth $50,785,000 after purchasing an additional 433,952 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Translate Bio in the 4th quarter worth approximately $118,000. Finally, Barclays PLC grew its stake in shares of Translate Bio by 82.8% in the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock worth $50,000 after purchasing an additional 3,039 shares during the last quarter. 59.27% of the stock is currently owned by institutional investors.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.